On Monday, May 23rd, Maryland’s Prescription Drug Affordability Board (PDAB) began its work to set caps on certain prescription drug costs.
The Board, established in 2019 through House Bill 768/Senate Bill 759, is charged with conducting cost reviews, determining which prescription drugs pose affordability challenges, and setting upper payment limits. Payment limits set by the Board apply to state and local government entities only, including state and county correctional facilities, state hospitals, health clinics at state-run colleges and universities, state and local health benefit plans, and the state’s Medicaid program.
During the May 23rd proceedings, the Board discussed the development of regulations, including establishing a definition for “upper payment limit,” and reviewed reports concerning generic medications and pharmaceutical distribution and payment. After the hearing, Maryland Matters interviewed one of the lead advocates in support of establishing the Prescription Drug Affordability Board:
During an interview after Monday’s hearing, Vincent C. DeMarco, the head of the Maryland Citizens’ Health Initiative, said that he is “thrilled” the board is making headway on imposing upper payment limits, adding that he knows each member is aware “that drugs don’t work if people can’t afford them.”
MACo supported establishing the PDAB during the 2019 legislative session.